T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy
Guido Ghilardi(Hospital of the University of Pennsylvania), Joseph A. Fraietta(University of Pennsylvania), James N. Gerson(Hospital of the University of Pennsylvania), Vivianna M. Van Deerlin(Hospital of the University of Pennsylvania), Jennifer J.D. Morrissette(Hospital of the University of Pennsylvania), Gabriel C. Caponetti(Hospital of the University of Pennsylvania), Luca Paruzzo(Hospital of the University of Pennsylvania), Jaryse Harris(Hospital of the University of Pennsylvania), Elise A. Chong(Hospital of the University of Pennsylvania), Sandra P. Susanibar-Adaniya(Hospital of the University of Pennsylvania), Jakub Svoboda(Hospital of the University of Pennsylvania), Sunita D. Nasta(Hospital of the University of Pennsylvania), Ositadimma Ugwuanyi(Hospital of the University of Pennsylvania), Daniel J. Landsburg(Hospital of the University of Pennsylvania), Eugenio Fardella(Hospital of the University of Pennsylvania), Adam Waxman(Hospital of the University of Pennsylvania), Emeline R. Chong(Hospital of the University of Pennsylvania), Vrutti Patel(Hospital of the University of Pennsylvania), Raymone Pajarillo(Hospital of the University of Pennsylvania), Irina Kulikovskaya(University of Pennsylvania), David Lieberman(Hospital of the University of Pennsylvania), Adam D. Cohen(Hospital of the University of Pennsylvania), Bruce L. Levine(University of Pennsylvania), Edward A. Stadtmauer(Hospital of the University of Pennsylvania), Noelle V. Frey(Hospital of the University of Pennsylvania), Dan T. Vogl(Hospital of the University of Pennsylvania), Elizabeth O. Hexner(Hospital of the University of Pennsylvania), Stefan K. Barta(Hospital of the University of Pennsylvania), David L. Porter(Hospital of the University of Pennsylvania), Alfred L. Garfall(Hospital of the University of Pennsylvania), Stephen J. Schuster(Hospital of the University of Pennsylvania), Carl H. June(University of Pennsylvania), Marco Ruella(Hospital of the University of Pennsylvania)
Cited by 251
Abstract
Related Papers
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
Bruce D. Cheson, Richard I. Fisher, Sally F. Barrington et al.|Journal of Clinical Oncology|2014|5.5k
RECIST 1.1—Update and clarification: From the RECIST committee
Lawrence H. Schwartz, Saskia Litière, Elisabeth G.E. de Vries et al.|European Journal of Cancer|2016|1.9k